{'fraction_non_alphanumeric': 0.029159519725557463, 'fraction_numerical': 0.012864493996569469, 'mean_word_length': 4.984615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ncRNAs-mediated upregulation of GTSE1 is involved in the poor prognosis and tumor immune infiltration of Clear Cell Renal Cell Carcinoma


 Aims: Examine GTSE1 expression and function in renal clear cell carcinoma, as well as the nc-RNA that is upstream of GTSE1.Methods: The Cancer Genome Atlas (TCGA) provided clinical and RNA-seq data for ccRCC patients, and the expression of GTSE1, its connection with clinical data, prognosis and tumor immune infiltration, and prediction of upstream noncoding RNAs (nc-RNAs) of GESE1 were analyzed using R language and public tumor databases.Results: In ccRCC, GTSE1 is highly expressed and is linked to a high clinical stage and a poor prognosis. In ccRCC, the PVT1 / has-mir-23b-3p / GTSE1 axis has been identified as the most likely upstream ncRNA related route of GTSE1. Furthermore, GTSE1 expression was linked to tumor immune cell infiltration, immune cell biomarker expression, and immunological checkpoint expression.Conclusions: Upregulation of GTSE1 by ncRNA is linked to poor prognosis and ccRCC tumor immune infiltration. GTSE1 has the potential to be a useful predictive biomarker as well as a therapeutic target.